ImaRx Licenses Tissue Destruction Patent; ImaRx Expands Intellectual Property Portfolio Related to Blood Clot Dissolution.TUCSON, Ariz. -- ImaRx Therapeutics Inc. (www.imarx.com) announced today that it has entered into an exclusive licensing agreement with Dr. Reinhard Schlief for his U.S. and international patents related to the use of microbubbles and ultrasound for the destruction of biological tissues. United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. patent No. 5,380,411 augments ImaRx's intellectual property portfolio for SonoLysis(TM), the company's proprietary bubble technology used to dissolve blood clots Blood Clots Definition A blood clot is a thickened mass in the blood formed by tiny substances called platelets. Clots form to stop bleeding, such as at the site of cut. . SonoLysis is expected to enter Phase II clinical trials for the treatment of acute ischemic stroke in first quarter of this year. Schlief, a distinguished inventor and scientist, pioneered applications for bubbles with ultrasound. He explained, "I felt that the best home for my patent would be ImaRx because of their extensive experience and developments in the field of bubbles and ultrasound. I am excited to see the intent of this patent come to fruition." Dr. Evan Unger, ImaRx's president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , stated, "We are pleased to have added Dr. Schlief's patent to our IP portfolio. We believe this patent is one of the earliest in the field of bubbles and ultrasound and it provides broad claims for therapy. Stroke is our lead indication for this technology and we consider that this patent further protects this area." On a related matter, two presentations will be made today at the International Stroke Conference in New Orleans highlighting the use of microbubbles and ultrasound to dissolve clots in stroke patients. Unger stated, "We regard these two presentations as important early evidence of the power of bubbles and ultrasound to augment t-PA for the treatment of stroke." About SonoLysis SonoLysis, a unique clot dissolving treatment, uses ultrasound to cavitate cavitate formation of cavities. gas-filled nanobubbles (smaller than one micron in size) to dissolve clots. ImaRx's proprietary nanobubbles are injected via catheter or intravenous injection and enter the site of the clot. The ultrasound releases specific pulse sequences activating the bubbles in the vicinity of the clot for final dissolution. About ImaRx ImaRx Therapeutics, a privately held biopharmaceutical company, is focused on the development of NanoInvasive(TM) medicine. ImaRx's clot dissolving technology is currently in Phase I/II clinical trials for the treatment of deep vein thrombosis A blood clot (thrombos) in a vein deep within the muscle, typically in the thigh or calf. It is caused by disease or the lack of activity such as sitting for hours at a computer screen. . Phase II clinical trials for the treatment of acute ischemic stroke are expected to begin in the first quarter 2005. ImaRx developed and out-licensed a microbubble mi·cro·bub·ble n. An extremely small bubble, usually only a few hundred micrometers in diameter, that can be uniformly suspended in a liquid such as blood. for a diagnostic ultrasound diagnostic ultrasound n. Use of ultrasound to obtain images for medical diagnostic purposes. contrast agent that is now marketed by Bristol-Myers Squibb. ImaRx retained all targeted and therapeutic rights to its technologies, which are protected by more than 100 issued patents. Forward-Looking Statement forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. This release contains forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the company's control, which may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. , and other regulatory authorities, and the company's success in raising capital. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion